ArticleScience translational medicine2017
Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity.
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04923958 (Rapid Research in Diagnostics Development for TB Network), which is not on this map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) Study
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Outlook for CRISPR-based tuberculosis assays now in their infancy.Frontiers in immunology · 2023Pooled it
- Diagnostic value of Lipoarabinomannan antigen for detecting Mycobacterium tuberculosis in adults and children with or without HIV infection.Journal of clinical laboratory analysis · 2022Pooled it
- A systematic review of biomarkers to detect active tuberculosis.Nature microbiology · 2019Pooled it
- Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients.The Journal of clinical investigation · 2020Trial
- Trial
- Trial
- Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial.Lancet (London, England) · 2018Trial
- Antigen heterogeneity in the development and clinical validation of a multiplexed urine test for tuberculosis.Communications medicine · 2026Article
- Characterization ofMicroorganisms · 2026Article
- Rapid urinary lipoarabinomannan test with laboratory-level sensitivity for tuberculosis detection: a performance evaluation.Microbiology spectrum · 2026Article
- Evaluation of urinary extracellular vesicles and microRNAs to diagnose urogenital tuberculosis.World journal of experimental medicine · 2025Article
- Nylon Affinity Networks Capture and Sequester Two Model Bacteria Spiked in Human Plasma.Pathogens (Basel, Switzerland) · 2025Article
- Clinical application of the urinary lipoarabinomannan (AIMLAM) test in PLHIV with TB.AIDS research and therapy · 2025Article
- Mass spectrometry-based discovery and diagnostic validation of T. cruzi antigens in the urine of congenitally infected Chagas Disease patients.PLoS neglected tropical diseases · 2025Article
- Review
- Value of urinary lipoarabinomannan levels for tuberculosis diagnosis and monitoring of therapy.Frontiers in microbiology · 2025Article
- A new strategy improving TB diagnosis: stratified urine LAM test based on lymphocyte counts.Frontiers in cellular and infection microbiology · 2025Article
- Improving the diagnosis of active tuberculosis: a novel approach using magnetic particle-based chemiluminescence LAM assay.BMC pulmonary medicine · 2024Article
- Urinary lipoarabinomannan in individuals with sputum-negative pulmonary tuberculosis.The Indian journal of medical research · 2024Article
- Diagnostic Efficiency of the Blood-Based Cepheid 3-Gene Host Response Test and Urine-Based Lipoarabinomannan for Active Tuberculosis Case Detection at a General Hospital in China.Infection and drug resistance · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 6 institutions in 5 countries.
Funding
Abstract
An accurate urine test for pulmonary tuberculosis (TB), affecting 9.6 million patients worldwide, is critically needed for surveillance and treatment management. Past attempts failed to reliably detect the mycobacterial glycan antigen lipoarabinomannan (LAM), a marker of active TB, in HIV-negative, pulmonary TB-infected patients' urine (85% of 9.6 million patients). We apply a copper complex dye within a hydrogel nanocage that captures LAM with very high affinity, displacing interfering urine proteins. The technology was applied to study pretreatment urine from 48 Peruvian patients, all negative for HIV, with microbiologically confirmed active pulmonary TB. LAM was quantitatively measured in the urine with a sensitivity of >95% and a specificity of >80% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.